Unlike full-length mAbs, however, fragments (unless designed otherwise) fail to induce effector functions that require an Fc domain, such as antibody ... six bispecific Fab candidate fragments ...

A new anti-HER2 IgE antibody potentially offers new therapy options for treatment-resistant breast and ovarian cancers.